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Abstract 
Purpose: To determine the sites of first distant relapse in patients with or without pCR following 
neoadjuvant chemotherapy in breast cancer patients enrolled in the EORTC 10994/BIG-1-00 trial. 
Methods: We included patients enrolled in the EORTC 10994/BIG-1-00 trial who received at least one 
chemotherapy cycle before surgery and who had been diagnosed with a distant relapse. pCR was 
defined as no evidence of residual invasive cancer in the primary tumor and axillary lymph nodes with or 
without residual ductal carcinoma in situ (DCIS). Site of first distant relapse was categorized as ‘soft 
tissue’, ‘visceral’, ‘skeletal’, ‘central nervous system (CNS)’ and ‘other’. The association between relapse 
site and achievement of pCR was assessed using multivariate logistic regression models for molecular 
subtypes classification and preceding locoregional recurrence. 
Results: The study included 383 (21%) eligible patients out of the 1,856 randomized, of whom 28 (7%) 
had achieved pCR. Median follow-up was 5.4 years. Achievement of pCR was associated with a trend 
towards a decreased presentation of skeletal metastases (21% (pCR) vs. 50% (non-pCR), OR=0.32, 
adjusted p-value=0.071) and an increase in the proportion of patients with CNS metastases as first 
distant relapse site (21% vs 9%, OR 2.39, adjusted p-value=0.183). Patients with pCR were more likely to 
present with only one relapse location category when compared to non-pCR (86% vs 69%). 
Conclusion: Patients that achieved a pCR appeared less likely to present with skeletal metastases and 
more frequently presented with CNS metastases as first site of distant relapse, even after adjustment 
for molecular subtypes. 
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Introduction 
Neoadjuvant systemic therapy is a well-established strategy for locally advanced disease with the aim of 
down staging the tumor to enable more conservative surgery. Additionally, over the last few years it is 
also increasingly applied in early-stage breast cancer patients requiring systemic treatment showing 
similar long-term outcome as compared to adjuvant administration[1–4]. The early administration of 
systemic therapy also permits ‘in-vivo’ monitoring of the efficacy of administered systemic treatment[5].  
The achievement of a pathologic complete response (pCR) after neoadjuvant treatment is associated with 
improved long-term survival and a decrease in both loco-regional and distant metastasis [5]. The pCR rate 
varies according to molecular subtype as does the association between pCR and long-term outcome, with 
the strongest correlation for the more aggressive subtypes [5–7]. 
The widely accepted explanation for this association is that the biology of the primary tumor and the 
micro metastatic disease are similar, and respond equally to the systemic neoadjuvant therapy. However, 
at least 10% of patients whose tumor achieved a pCR develop a recurrence within 5 years and more than 
two thirds of patients whose tumor did not achieve a pCR will not relapse [5]. In patients with triple 
negative tumors, in whom neither adjuvant hormonal nor trastuzumab therapies are going to interfere 
with the association between pCR and outcome, 15 to 20% of patients whose tumor achieved a pCR 
develop a recurrence within 5 years and 50% of patients whose tumor did not achieve a pCR will not 
relapse[5, 6, 8]. Thus, although pCR is a good prognosticator for survival it is not perfect. Several series 
have reported differences in estrogen receptor (ER) or human epidermal growth receptor 2 (HER2) status 
between the primary tumor and distant metastases in up to 32% and 14.5%, respectively[9, 10]. The 
biology of the micrometastatic disease in distant sites is certainly more complex than the biology of the 
primary tumor[11]. One could hypothesize that the correlation between pCR and survival is excellent in 
some specific sites while it remains poor in other sites. The first obvious example would be central nervous 
system metastasis. To our knowledge this question has never been addressed. 
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The aim of this study was to evaluate whether the sites of first distant relapse differed  between patients 
whose tumor achieved a pCR after neoadjuvant chemotherapy versus those who did not in the EORTC 
10994/BIG-1-00 trial[12]. 
 
Methods 
Study design, eligibility and treatment  
The EORTC 10994/BIG 1-00 trial enrolled patients aged ≤70 years with large operable or locally 
advanced/inflammatory breast cancer without evidence of distant metastases, who were candidates for 
neoadjuvant treatment. Patients were randomly assigned to receive either six cycles of anthracycline-
based chemotherapy (FEC) or a taxane-based regimen, docetaxel for three cycles followed by epirubicin 
+ docetaxel for three cycles (T-ET), all given prior to primary surgery. Subsequent locoregional treatment 
was determined according to guidelines described in the study protocol.  Women with hormone 
receptor positive tumors were recommended to receive adjuvant endocrine therapy for 5 years. 
Patients with HER2 positive tumors were allowed to enter adjuvant clinical trials assessing trastuzumab 
or to receive this treatment in the adjuvant setting when it became standard practice[12].   
For this sub-study we selected a subgroup of patients based on the following criteria: (i) Patients eligible 
in the EORTC 10994/BIG 1-00 trial, (ii) patients who received at least one cycle of neoadjuvant 
chemotherapy and who underwent surgery, (iii) patients who had a known pathological response status, 
and (iii) patients diagnosed with a distant relapse after surgery of which the site was specified. Patients 
with T4d tumors or who received radiotherapy before surgery were excluded from the analysis. 
Pathologic complete response was defined in this sub-study as no evidence of residual invasive cancer (or 
very few scattered tumor cells) in the primary tumor and axillary lymph nodes with or without residual 
ductal carcinoma in situ (DCIS). Information on Ki-67 was not collected within the main study. Therefore, 
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tumor subtype classification was performed according to the simplified approach as proposed in the 2011 
St. Gallen consensus, where Ki-67 is replaced by tumor grade [13] (Supplement A). Tumour histology, 
grade, ER, progesterone receptor (PgR) and HER2 status were based on local pathology assessment of the 
diagnostic biopsy. 
Objectives and end-points 
The primary objective of this study was to assess whether there are differences in the sites of first distant 
relapse between patients who achieved a pCR after neoadjuvant chemotherapy versus those who did not 
(non-pCR). Secondary objectives included 1) describing the differences in site of first distant relapse in the 
pCR and non-pCR groups by breast cancer subtype, 2) describing the clinicopathological characteristics of 
patients according to site of first distant relapse, 3) evaluating the effect of a preceding or concomitant 
locoregional recurrence (LR) on the occurrence of a specific site as first distant relapse, 4) studying the 
association between concomitant sites of first distant relapse.  
We evaluated the first site of distant relapse as reported in the case report forms, i.e. ‘soft tissue’, 
‘visceral’, ‘skeletal’, ‘CNS’ or ‘other’. In case of multiple lesions, all concomitant lesions at first presentation 
were included. As part of the secondary objectives, invasive locoregional recurrences were considered if 
they occurred before or at the same time of the first distant relapse. Locoregional recurrences were 
ipsilateral invasive breast recurrences and regional recurrences (chest wall and regional lymph nodes: 
axillary, internal mammary, infra and supraclavicular). 
Statistical analysis 
A statistical analysis plan was prospectively developed. The association between the occurrence of a 
specific site of first distant relapse and pCR status was evaluated using four multivariate logistic regression 
models, one for each site (‘soft tissue’, ‘visceral’, ‘skeletal’, ‘CNS’) except ‘other’, adjusting for intrinsic 
subtype and preceding locoregional recurrence (yes/no). Sites of first distant relapse classified as ‘other’ 
were not evaluated because the obtained estimation would have not been interpretable due to the 
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heterogeneity of the corresponding sites. The association with pCR was assessed using the Wald chi-
square test with adjusted p-values for multiple testing (Benjamini-Hochberg correction). A p-value <0.05 
was considered statistically significant. Sensitivity analyses were subsequently performed, with univariate 
and multivariate models adjusting for age, clinical tumor and nodal status, histologic tumor type, subtype 
and allocated chemotherapy regimen. Differences in site of first distant relapse between the molecular 
subtypes according to pCR-status, patient and tumor characteristics, and the presence of preceding 
locoregional recurrence per relapse site, and the occurrence of concomitant sites of first distant relapse 
were tabulated (no formal statistical testing was done due to the limited number of patients in the 
subgroups).  
All statistical analyses were performed using SAS software version 9.4 (SAS Institute). 
 
Results 
Of the 1,856 patients randomized in the trial, 383 patients diagnosed with a distant relapse were eligible 
for this substudy, of whom 28 (7%) were in the pCR-group and 355 (93%) in the non-pCR group. Reasons 
for ineligibility are shown in the consort diagram (Supplement B). The median follow-up was 5.4 years 
from date of randomization. Baseline patient and tumor characteristics according to pCR status are 
presented in Table 1. Median age of included patients was 49 years and most patients had clinically node 
positive disease (271/383; 71%). Overall, visceral (197/383; 51%) and skeletal metastases (185/383; 48%) 
were the most common sites of first distant relapse (Table 2). 
Association between pCR status and site of first distant relapse 
Patients whose tumor achieved pCR were less likely to present with skeletal metastases as compared to 
non-pCR patients (6/28 (21%) vs. 179/355 (50%) patients; OR 0.32, 95% CI 0.12-0.82; P=0.071, Table 2). A 
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similar trend was observed in all subtypes apart from Luminal A-like, though the numbers are very small 
(Table 3). 
Conversely, the proportion of patients with CNS metastasis as first metastatic site was numerically higher 
in the pCR-group as compared to in the non-pCR group (6/28 (21%) vs. 32/355 (9%) patients; OR 2.39, 
95% CI 0.87-6.58; P=0.183, Table 2). This difference was greatest in the HER2+ Luminal B-like subtype 
(Table 3). These differences in the incidence of skeletal and CNS metastases between patients whose 
tumor did or did not achieve pCR remained after further adjustment for age, histologic type, clinical node 
and tumor status, subtype and received chemotherapy regimen (data not shown).  
For the remaining sites (soft tissue and visceral) we did not observe an association with pCR status (Tables 
2).  
Clinicopathological characteristics of patients according to site of first distant relapse 
Patients with soft tissue and CNS metastases were older and had higher grade tumors as compared to 
patients with visceral and skeletal metastases (Table 4). Patients presenting with skeletal metastasis more 
frequently had tumors with a lobular histology, a lower-grade (I and II), and a luminal-like subtype (17%, 
54%, and 59% respectively). Patients presenting with CNS metastases were predominantly clinically node 
positive (84% N+ vs. 16% N0, Table 4). Furthermore, in these patients we observed a higher rate of 
HER2+/non-luminal and TN breast cancer.  
Preceding locoregional recurrence 
In 68 patients, the first distant relapse was preceded by or occurred concomitantly with a locoregional 
recurrence (Table 1). The proportion of patients with a prior LR was highest in those presenting with soft 
tissue metastases (18/47 (38%) versus 13% (CNS) to 19% (visceral) in the other groups (Table 4)). We did 
not observe differences in site of first distant relapse according to pCR status for patients that did or did 
not have a preceding LR event (results not shown).    
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Association between pCR status and extent of metastatic disease 
The proportion of patients who presented with more than one site of metastatic spread was numerically 
lower in the group of patients whose tumor achieved a pCR as compared to patients in the non-pCR group 
(4/28 (14%) vs. 112/355 (32%) patients with >1 relapse site, Table 5). Patients with soft tissue as first site 
of distant relapse most frequently presented with at least one other metastatic site (32/47 patients 
(68%)). In 60% of patients with CNS as first site of distant relapse, the CNS was the only site of metastatic 
disease. Skeletal and visceral metastases were the most common combination in case of more than one 
site of relapse (70 out of 116 patients (60%) with >1 metastatic site, Table 5).  
Discussion 
In this study, there was a numerical difference in presentation with CNS metastasis, with a higher 
incidence in the pCR group (Odds Ratio 2.39). Of note, CNS metastasis accounted for one fifth of all first 
distant metastasis in the pCR group. This finding supports the concept of the brain being a sanctuary site 
where malignant cells are protected from anti-cancer therapeutics by the blood-brain barrier[14]. Patients 
with a non-luminal HER2+ or TN subtype have higher pCR rates as compared to patient with luminal 
subtypes[5] and have been shown to more frequently metastasize to the brain and viscera[15, 16]. Thus, 
an excess of CNS metastases in the pCR group might be expected in the non-luminal HER2+ and TN 
subtypes.  
Furthermore, patients whose tumor achieved a pCR had a lower rate of skeletal metastasis as first site of 
distant relapse as compared to patients whose tumor did not achieve pCR (Odds Ratio 0.32). This observed 
difference could perhaps have been explained by a molecular subtype bias. Patients with a luminal 
subtype are less likely to achieve a pCR and are known to more frequently metastasize to skeletal 
tissue[17, 18]. 
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We also evaluated the influence of a preceding LR, since such an event could have an influence on the 
subsequent distant metastatic spread as these patients might receive additional systemic treatment. 
Furthermore, the local recurrence itself could give rise to metastatic spread. We did not observe a 
statistically significant association between a prior LR and any site of first distant relapse after adjustment 
for pCR status and subtype. These results should be interpreted with caution since the number of LRs 
preceding distant relapses was relatively low.   
The median follow-up of patients included in this study was 5.4 years. This time-frame will have an 
influence on the distribution of relapse sites we observed. Previous studies have shown that patients with 
a shorter disease-free survival (DFS) more often present with visceral and CNS metastases[19]. The 
incidence of these metastatic sites reaches its peak in the second year of follow-up after which the 
incidence declines, whereas bone metastases can even occur later on. Furthermore, patients with a 
shorter DFS are more often of the TN subtype which is known to metastasize frequently to the visceral 
tissue as is also demonstrated in this study[8, 20, 21]. Longer follow-up is needed. 
This study has strengths and limitations. A major strength of the study is that the population consists of 
patients from a large randomized trial with a total of 383 patients with events of interest. The main 
limitation is the small number of patients in the pCR group, which prohibits drawing firm conclusions from 
this study. This limitation is even more important when trying to analyze the results by molecular 
subtypes. It is well known that the metastatic behavior and prognosis of breast cancer is dependent on 
tumor biology of the different intrinsic subtypes[22]. We attempted to adjust for possible molecular 
subtype bias by performing multivariate analyses.  
In conclusion, there appear to be differences in the occurrence of tissue-specific sites of first distant 
relapse between patients that achieved pCR after neoadjuvant chemotherapy when compared to those 
that did not, even after adjustment for molecular subtypes. The trends observed in the present study 
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need to be confirmed in a meta-analysis as well to establish the clinical implication on long-term 
prognosis.  
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Table 1. Baseline characteristics of 383 included patients 
 pCR 
N= 28 
non-pCR 
N= 355 
Total 
N= 383 
 N % N % N % 
Median age at diagnosis 48 49 49 
Age at diagnosis       
≤40     7 25.0    83 23.4    90 23.5 
41-50     9 32.1   123 34.6   132 34.5 
51-70    12 42.9   149 42.0   161 42.0 
Menopausal status       
Premenopausal    15 53.6   207 58.3   222 58.0 
Postmenopausal    13 46.4   148 41.7   161 42.0 
cT stage       
T1-2    11 39.3   126 35.5   137 35.8 
T3    15 53.6   160 45.1   175 45.7 
T4     2 7.1    69 19.4    71 18.5 
cN stage       
N0    13 46.4    97 27.3   110 28.7 
N1    13 46.4   224 63.1   237 61.9 
N>1     2 7.1    32 9.0    34 8.9 
Unknown     0 0.0     2 0.6     2 0.5 
Tumor histology       
Ductal    26 92.9   291 82.0   317 82.8 
Lobular     2 7.1    43 12.1    45 11.7 
Other     0 0.0    18 5.1    18 4.7 
Missing     0 0.0     3 0.8     3 0.8 
Tumor grade       
I     0 0.0    14 3.9    14 3.7 
II    12 42.9   153 43.1   165 43.1 
III    16 57.1   130 36.6   146 38.1 
Not assessed/Unknown     0 0.0    58 16.4    58 15.1 
Subtype       
Luminal A-like     3 10.7    82 23.1    85 22.2 
Luminal B-like (HER2-negative)     1 3.6    42 11.8    43 11.2 
Luminal B-like (HER2-positive)     6 21.4    64 18.0    70 18.3 
HER2+, non luminal-like     6 21.4    34 9.6    40 10.4 
Triple negative     6 21.4    55 15.5    61 15.9 
Unknown     6 21.4    78 22.0    84 21.9 
Neoadjuvant chemotherapy regimen       
FEC    17 60.7   193 54.4   210 54.8 
T-ET    11 39.3   162 45.6   173 45.2 
Number of cycles       
1 0 0.0     1 0.3 1 0.3 
2 0 0.0 3 0.8 3 0.8 
3 0 0.0 5 1.4 5 1.3 
4 0 0.0 5 1.4 5 1.3 
5 1 3.6 4 1.1 5 1.3 
6 27 96.4 337 94.9 364 95.0 
Type of surgery       
BCS    15 53.6   100 28.2   115 30.0 
Mastectomy    13 46.4   254 71.5   267 69.7 
Unknown     0 0.0     1 0.3     1 0.3 
Preceding locoregional recurrence       
No 21 75.0 294 82.8 315 82.2 
Yes 7 25.0 61 17.2 68 17.8 
BCS= Breast-conserving surgery; pCR= pathological Complete Response; cT= clinical Tumor; cN= clinical lymph Nodes, FEC= 
5-fluorouracil, epirubicin and cyclophosphamide, T-ET= docetaxel x3  epirubicin + docetaxel x3 
Percentages may not add up to 100% due to rounding 
 
 
Page 15 of 20 
 
Table 2. Association between site of first distant relapse and pCR status after neoadjuvant chemotherapy 
 pCR 
N=28 
non-pCR 
N=355 
Total 
N=383 
Univariate 
pCR vs. non-pCR 
Multivariatea 
pCR vs. non-pCR 
 N (%) N (%) N (%) OR (95% CI) OR (95% CI) Adj. P-value 
Soft tissue       
No 24 (86%) 312 (88%) 336 (88%) 
1.21 (0.40-3.65) 0.94 (0.30-2.95) .909 Yes 4 (14%) 43 (12%) 47 (12%) 
Visceral       
No 14 (50%) 172 (48%) 186 (49%) 
0.94 (0.44-2.03) 0.80 (0.36-1.74) .756 Yes 14 (50%) 183 (52%) 197 (51%) 
Skeletal       
No 22 (79%) 176 (50%) 198 (52%) 
0.27 (0.11-0.68) 0.32 (0.12-0.82) .071 Yes 6 (21%) 179 (50%) 185 (48%) 
CNS       
No 22 (79%) 323 (91%) 345 (90%) 
2.75 (1.04-7.29) 2.39 (0.87-6.58) 
 
Yes 6 (21%) 32 (9%) 38 (10%) .183 
Other       
No 24 (86%) 292 (82%) 316 (83%) 
0.77 (0.26-2.31) 0.73 (0.24-2.22) NA
b 
Yes 4 (14%) 63 (18%) 67 (17%) 
pCR= pathological Complete Response, CNS=Central Nervous System 
aAdjusted for subtype and preceding locoregional relapse (yes/no) 
bThe odds-ratio for the ‘other’ category is displayed without the corresponding P-value, bringing the number of 
P-values included in the Benjamini-Hochberg correction to 4-tested values. 
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Table 3. Site of first distant relapse according to pCR status per tumor subtype 
 Lum-A Lum-B (HER2-) 
Lum-B 
(HER2+) HER2+ Triple Negative Unknown 
 pCR 
N=3 
non-
pCR 
N=82 
pCR 
N=1 
non-pCR 
N=42 
pCR 
N=6 
non-
pCR 
N=64 
pCR 
N=6 
non-
pCR 
N=34 
pCR 
N=6 
non-pCR 
N=55 
pCR 
N=6 
non-
pCR 
N=78 
Soft tissue             
   N  0 4 0 4 1 10 1 6 1 8 1 11 
   % 0% 5% 0% 10% 17% 16% 17% 18% 17% 15% 17% 14% 
Visceral             
   N 1 36 1 14 3 38 4 19 4 33 1 43 
   % 33% 44% 100% 33% 50% 59% 67% 56% 66% 60% 17% 55% 
Skeletal             
   N 2 50 0 26 1 31 1 12 1 17 1 43 
   % 67% 61% 0% 62% 17% 48% 17% 35% 17% 31% 17% 55% 
CNS             
   N 0 2 0 2 2 3 1 5 1 8 2 12 
   % 0% 2% 0% 5% 33% 5% 17% 15% 17% 15% 33% 15% 
Other             
   N 0 12 0 7 1 10 0 7 1 9 2 18 
   % 0% 15% 0% 17% 17% 16% 0% 21% 17% 16% 33% 23% 
CNS=Central Nervous System 
Percentages displayed for column 
Patients could have presented with multiple sites of relapse then percentages are not cumulative 
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Table 4. Patient, tumor and treatment characteristics according to site of first distant relapse 
 Soft tissue 
N=47 
Visceral 
N=197 
Skeletal 
N=185 
CNS 
N=38 
Other 
N=67 
 N % N % N % N % N % 
Median age at diagnosis 50 yrs 48 yrs 48 yrs 53 yrs 49 yrs 
Age at diagnosis           
≤40     8 17.0    43 21.8    54 29.2     7 18.4    16 23.9 
41-50    16 34.0    80 40.6    59 31.9    10 26.3    27 40.3 
51-70    23 48.9    74 37.6    72 38.9    21 55.3    24 35.8 
Menopausal status           
Premenopausal    24 51.1   121 61.4   112 60.5    19 50.0    39 58.2 
Postmenopausal    23 48.9    76 38.6    73 39.5    19 50.0    28 41.8 
cT stage           
T1-2    13 27.7    69 35.0    66 35.7    14 36.8    23 34.3 
T3    18 38.3    93 47.2    85 45.9    16 42.1    33 49.3 
T4    16 34.0    35 17.8    34 18.4     8 21.1    11 16.4 
cN stage           
N0    17 36.2    64 32.5    50 27.0     6 15.8    18 26.9 
N1    19 40.4   118 59.9   123 66.5    25 65.8    42 62.7 
N>1    10 21.3    14 7.1    12 6.5     7 18.4     7 10.4 
Unknown     1 2.1     1 0.5     0 0.0     0 0.0     0 0 
Tumor histology           
Ductal    39 83.0   169 85.8   145 78.4    32 84.2    52 77.6 
Lobular     3 6.4    16 8.1    32 17.3     4 10.5    12 17.9 
Other     5 10.6    11 5.6     7 3.8     1 2.6     2 3.0 
Missing     0 0.0     1 0.5     1 0.5     1 2.6     1 1.5 
Tumor grade           
I     0 0.0     6 3.0     8 4.3     0 0.0     0 0.0 
II    13 27.7    85 43.1    92 49.7    14 36.8    30 44.8 
III    24 51.1    74 37.6    59 31.9    18 47.4    25 37.3 
Not assessed/Unknown    10 21.3    32 16.2    26 14.1     6 15.8    12 17.9 
Subtype           
Luminal-A     4 8.5    37 18.8    52 28.1     2 5.3    12 17.9 
Luminal-B (HER2-negative)     4 8.5    15 7.6    26 14.1     2 5.3     7 10.4 
Luminal-B (HER2-positive)    11 23.4    41 20.8    32 17.3     5 13.2    11 16.4 
HER2+, non-luminal     7 14.9    23 11.7    13 7.0     6 15.8     7 10.4 
Triple negative     9 19.1    37 18.8    18 9.7     9 23.7    10 14.9 
Unknown    12 25.5    44 22.3    44 23.8    14 36.8    20 29.9 
Neoadjuvant regimen           
FEC    28 59.6   101 51.3   112 60.5    21 55.3    34 50.7 
T-ET    19 40.4    96 48.7    73 39.5    17 44.7    33 49.3 
Type of surgery           
BCS    10 21.3    59 29.9    51 27.6    11 28.9    22 32.8 
Mastectomy    37 78.7   137 69.5   133 71.9    27 71.1    45 67.2 
Unknown     0 0.0  1 0.5     1 0.5     0 0.0     0 0.0 
Preceding locoregional recurrence           
No    29 61.7   159 80.7   158 85.4    33 86.8    52 77.6 
Yes    18 38.3    38 19.3    27 14.6     5 13.2    15 22.4 
BCS= breast-conserving surgery; pCR= pathological Complete Response; cT= clinical Tumor; cN= clinical lymph 
Nodes; CNS= Central Nervous System, FEC= 5-fluorouracil, epirubicin and cyclophosphamide, T-ET= docetaxel x3  
epirubicin + docetaxel x3 
Percentages are displayed for columns. Percentages may not add up to 100% due to rounding. 
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Table 5. Occurrence of concomitant sites of first distant relapse 
5A. Number of concomitant sites of first distant relapse 
 
 Number of concomitant sites of first distant relapse 
 One single site 
N= 267 
More than 1 site 
N= 116 
 N % N % 
pCR status     
pCR 24 85.7 4 14.3 
Non-pCR 243 68.5 112 31.5 
Site of relapse     
Soft tissue 15 31.9 32 68.1 
Visceral 103 52.3 94 47.7 
Skeletal 96 51.9 89 48.1 
CNS 23 60.5 15 39.5 
Other 30 44.8 37 55.2 
pCR= pathological Complete Response; 
Percentages are displayed for rows. Number of patients by site of relapse for 
those with more than one sites of relapse are not cumulative. 
 
5B. Distribution of concomitant sites of first distant relapse 
 
Sites of first 
distant relapse 
Patients with more than one relapse site category  
(N=116) 
Soft tissue Visceral Skeletal CNS Other 
Yes 
N=32 
No 
N=84 
Yes 
N=94 
No 
N=22 
Yes 
N=89 
No 
N=27 
Yes 
N=15 
No 
N=101 
Yes 
N=37 
No 
N=79 
Soft tissue N   21 11 20 12 4 28 11 21 %   22.3% 50% 22.5% 44.4% 26.7% 27.7% 29.7% 26.6% 
Visceral N     70 24 10 84 26 68 %     78.7% 88.9% 66.7% 83.2% 70.3% 86.1% 
Skeletal N       7 82 21 68 %       46.7% 81.2% 56.8% 86.1% 
CNS N         1 14 %         2.7% 17.7% 
Other N           %           
Percentages displayed for column and are not cumulative. 
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 Supplement A: Simplified breast cancer subtype classification proposed by the 2011 St. Gallen consensus 
Breast cancer subtype ER status PgR status Her2 status Tumor grade 
Luminal-A like ER+            and/or PgR+ Her2- Grade 1 or 2 
Luminal-B like (HER2-) ER+            and/or PgR+ Her2- Grade 3 
Luminal-B like (HER2+) ER+            and/or PgR+ Her2+ Any 
HER2+, non-luminal ER- PgR- Her2+ Any 
Triple Negative ER- PgR- Her2- Any 
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Supplement B: Consort diagram 
 
 
1856 randomised patients from EORTC 10994/BIG 1-00 trial 
1473 ineligible patients*: 
- 22 ineligible in the p53 trial protocol**                         
- 1334 were not diagnosed with a distant relapse 
- 1 did not have a specified site of first distant relapse 
- 6 did not receive at least one cycle of neoadjuvant chemotherapy 
- 31 received radiotherapy before surgery                          
- 154 had T4d tumour                         
- 110 experienced disease progression before surgery                     
- 54 had a non-assessable pCR status                       
383 eligible patients 
355 non-pCR patients 28 pCR patients 
* Patients can be ineligible for more than one reason. 
** Reasons for ineligibility are listed in the original 10994 trial publication[12] 
